期刊文献+

阿维莫泮非对映异构体的合成与表征

Synthesis and characterization of the diastereoisomer of Alvimopan
下载PDF
导出
摘要 以(αR,3R,4R)-4-(3-羟基苯基)-3, 4-二甲基-2-(苯基甲基)-1-哌啶丙酸甲酯为起始原料,经水解、缩合、水解三步反应得到阿维莫泮非对映异构体杂质[[2R)-[[4(R)-(3-羟基苯基)-3(R), 4-二甲基-1-哌啶基]甲基]-1-氧代-3-苯基丙基]氨基]乙酸。经NMR、IR、MS和HPLC对合成产物的结构及纯度进行了表征,确证为目标化合物,纯度达98.0%以上,可作为阿维莫泮药物质量控制的杂质对照品。 The diastereroisomer of Alvimopan, named [[2(R)-[[4(R)-(3-hydroxyphenyl)-3(R), 4-dimethyl-1-piperidine]methyl]-1-oxo-3-phenyl propionic acid, was synthesized via three step reactions using(αR, 3R, 4R)-4-(3-hydroxyphenyl)-3, 4-dimethyl-2-(phenylmethyl)-1-piperidine propionate as starting material. The structure of the target compound was confirmed by NMR, IR and MS, with the purity was tested by HPLC to be more than 98%, which means the synthesized diastereroisomer can be used as the reference substances of the impurities in the quality control of alvimopan.
作者 熊先水 刘昆明 熊道陵 曾庆建 王立平 欧阳少波 XIONG Xian-shui;LIU Kun-ming;XIONG Dao-ling;ZENG Qing-jian;WANG Li-ping;OUYANG Shao-bo(Jiangxi Qingfeng Pharmaceutical Co., Ltd.Ganzhoo , Jiangxi 321000;School of Metallurgy and Chemical Engineering, Jiangxi University of Science and Technology, Ganzhou, Jiangxi 341000)
出处 《赣南医学院学报》 2019年第4期337-340,共4页 JOURNAL OF GANNAN MEDICAL UNIVERSITY
基金 江西省教育厅科技项目(No.GJJ160668,No.GJJ170547) 赣州市2018年市级科技计划项目(赣市科发〔2018〕50号) 江西理工大学大学生创新创业训练计划项目(No.XZG-16-08-12) 江西理工大学博士启动经费资助项目
关键词 阿维莫泮 非对映异构体 杂质 合成 表征 Alvimopan Diastereoisomer Impurity Synthesis Characterization
  • 相关文献

参考文献5

二级参考文献20

  • 1刘建祖,郭玉芳,邱雪莲.红霉素促进腹部手术后胃肠运动功能恢复的临床研究[J].中国中西医结合外科杂志,2007,13(4):366-368. 被引量:12
  • 2江志伟,李宁,黎介寿.术后肠麻痹临床表现及病理生理机制[J].中国实用外科杂志,2007,27(9):682-683. 被引量:177
  • 3William K Schmidt. Alvimopan (ADL 8-2698) is anovel peripheral opioid antagonist [J]. Am J Surg,2001,182(5) : 27s -38s.
  • 4Wolff BG, Michelassi F,Gerkin TM, et al, Alvi-mopan, a novel, peripherally acting mu opioid an-tagonist: results of a multicenter, randomized,double-blind, placebo-controlled . phase III trial ofmajor abdominal surgery and postoperative ileus[J].Ann Surg,2004,240(4) : 728 - 735.
  • 5Conor P. Delaney, James L. Weese,Neil H. Hy-man, et al. Phase III trial of alvimopan, a novel,peripherally acting,mu opioid antagonist, for post-operative ileus after major abdominal surgery [J].Dis Colon Rectum,2005 ,48(6) : 1114-1125.
  • 6Webster L,Jansen JP, Peppin J,et al. Alvimopan,a peripherally acting mu-opioid receptor (PAM-OR)antagonist for the treatment of opioid-induced boweldysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study insubjects taking opioids for chronic non-cancer pain[J]. Pain, 2008,137(2) : 428 - 440.
  • 7Beattie DT, Cheruvu M,Mai N, et al. The in vitropharmacology of the peripherally restricted opioidreceptor antagonists, alvimopan, ADL 08-0011 andmethylnaltrexoneCJ]. Naunyn Schmiedebergs ArchPharmacol,2007 , 375(3) :205 -220.
  • 8JF Foss,VD Schmith, B. Wallin,et al. Alvimopan(enteregTM) , a novel opioid antagonist, achievesactive systemic concentrations [ J ]. Clin PharmacolTher,2005,77(2): 74.
  • 9Foss JF, Fisher DM, Schmith VD. Pharmacokinet-ics of alvimopan and its metabolite in healthy volun-teers and patients in postoperative ileus trials [J].Clin Pharmacol Ther,2008 ,83(5): 770-776.
  • 10Schmith VD, Johnson BM, Vasist LS,et al. Theeffects of a short course of antibiotics on alvimopanand metabolite pharmacokinetics[J]. J Clin Pharma-col, 2010 .50(3) : 338-349.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部